Apolipoprotein A-I mimetics attenuate macrophage activation in chronic treated HIV

Conclusion: Given that gut barrier dysfunction and macrophage activation are contributors to comorbidities like cardiovascular disease in HIV, apoA-I mimetics should be tested as therapy for morbidity in chronic treated HIV.
Source: AIDS - Category: Infectious Diseases Tags: BASIC SCIENCE Source Type: research